QIAGEN Names Former Beckman Coulter President as CEO

There’s a new leader moving into QIAGEN N.V.’s corner office.

The company has appointed Jonathan M. Pratt as CEO to succeed Thierry Bernard, who will step down from the top spot (and his role as managing director) to support an orderly transition through the end of the year. Pratt will assume his chief executive duties on Sept. 1.

“The Supervisory Board unanimously concluded that Jon Pratt is the right leader for QIAGEN’s next phase,” QIAGEN Supervisory Board Chairman Stephen H. Rusckowski said. “Jon combines deep knowledge of our markets with a strong international record of strengthening commercial execution and operational performance. His experience across life sciences and laboratory technologies is directly relevant to QIAGEN’s portfolio and customers. Building on our strong foundation, we are confident he will advance our commitment to solid, profitable growth. On behalf of the Supervisory Board, I also want to thank Thierry Bernard for his leadership, his many contributions to QIAGEN, and his support in ensuring continuity during this transition.”

Pratt has more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. He most recently served as president and CEO of Filtration Group, leading the business through the completion of its sale to Parker-Hannifin Corporation earlier this month. He previously was senior vice president of the Waters Division at Waters Corporation and also served as president of Beckman Coulter Life Sciences, a Danaher company, and held senior leadership positions at Pall Corporation.

Throughout his career, Pratt has led global businesses spanning analytical instruments, laboratory technologies, software, consumables, services, and bioprocessing applications. His experience includes commercial execution, portfolio management, operations, and organizational development in markets closely aligned with QIAGEN’s portfolio and customer workflows.

Pratt earned a bachelor of science degree in chemistry from the University of Reading in the United Kingdom and an MBA from New York University Stern School of Business.

The new CEO appointment follows a comprehensive search process. Pratt was selected for his global industry knowledge, international leadership experience, and proven track record of improving performance across global businesses. He will also be proposed for shareholder approval as a managing director at an Extraordinary General Meeting planned for the final quarter this year.

“QIAGEN is an iconic and trusted brand in life sciences and molecular diagnostics, built on scientific rigor, quality, and technologies that support critical laboratory workflows worldwide,” Pratt stated. “What attracted me to QIAGEN is the combination of talented teams, a differentiated portfolio and close customer relationships. My first priority will be to listen to QIAGEN teams and customers, learn more about the business and understand where we can sharpen our choices, strengthen execution, and create greater impact. I look forward to working with the team to advance our vision of making improvements in life possible.”

A Netherlands-based holding company, QIAGEN N.V. bills itself as a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Its Sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the life sciences (academia, pharmaceutical R&D, and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed approximately 5,500 people in more than 35 locations.